Benzinga | Jan 28, 2022 06:28AM EST

SVB Leerink Maintains Underperform on Moderna, Lowers Price Target to $85

SVB Leerink analyst Mani Foroohar maintains Moderna (NASDAQ:MRNA) with a Underperform and lowers the price target from $86 to $85.